Corcept Therapeutics Inc. Announces Presentations On Mifepristone For The Treatment Of Patients With Hypercortisolism At American Association of Clinical Endocrinologists 26th Annual Congress

MENLO PARK, CA--(Marketwired - May 04, 2017) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced that presentations about hypercortisolism and mifepristone's role in treating that disorder will be presented at the 26th Annual Congress of the American Association of Clinical Endocrinologists (AACE) being held at the Austin Convention Center in Austin, Texas.

"There is growing awareness that even less severe degrees of hypercortisolism are harmful," said Joseph K. Belanoff, M.D., Corcept's Chief Executive Officer. "As a result, physicians are increasingly screening patients whose metabolic and cardiovascular symptoms have not responded to conventional therapy and finding cases of previously undetected Cushing's syndrome."

In addition to viewing the posters described below, AACE attendees may attend "Evolving Paradigms of Hypercortisolism," a product theater talk by Ty Carroll, M.D. Corcept is a sponsor of the talk.

----------------------------------------------------------------------------
                            Thursday, May 4, 2017                           
----------------------------------------------------------------------------
             Poster #124                                                    
 Screening of Diabetic Patients Using                                       
                U500                                                        
Insulin Uncovers a High Percentage of     Joseph W. Mathews, M.D., FACE     
     Undiagnosed Hypercortisolism              James J. Smith, PhD          
             Consistent                                                     
        with Cushing Syndrome                                               
----------------------------------------------------------------------------
                    Friday, May 5, 2017, 12:45 - 1:30pm                     
                              Product Theater B                             
----------------------------------------------------------------------------
        Evolving Paradigms of                                               
           Hypercortisolism                      Ty Carroll, M.D.           
----------------------------------------------------------------------------
                             Friday, May 5, 2017                            
----------------------------------------------------------------------------
             Poster #131                                                    
      Medical Management of Mild                                            
     Hypercortisolism and Primary                                           
   Aldosteronism in a Patient with            Sandi-Jo Galati, M.D.         
    ACTH-Independent Macronodular         Michele Lamerson, RN, MS, CPNP    
             Hyperplasia                                                    
      Presenting with Resistant                                             
            Hypertension                                                    
----------------------------------------------------------------------------
                                     Adriana G. Ioachimescu, M.D., PhD, FACE
             Poster #608                  Jonathan G. Ownby, M.D., FACE     
   Improving Glycemic Control with       Nicole G. Greyshock, M.D., FACE    
            Mifepristone                   Thomas C. Jones, M.D., FACE      
in Cushing Syndrome Patients May Lead     Gary S. Wand, M.D., PhD, FACE     
     to Significant Weight-loss                James J. Smith, PhD          
----------------------------------------------------------------------------
             Poster #725                                                    
  Successful Medical Management with           Saima Farghani, M.D.         
Mifepristone in a Patient with Occult     Michele Lamerson, RN, MS, CPNP    
      Ectopic Cushing Syndrome                                              
----------------------------------------------------------------------------
             Poster #836                                                    
  Mifepristone Therapy Significantly                                        
              Improved                                                      
Insulin Resistance, Glycemic Control,     Jonathan G. Ownby, M.D., FACE     
  and Weight Loss in a Patient with            James J. Smith, PhD          
           Cushing Disease                                                  
 Previously Treated with Pasireotide                                        
----------------------------------------------------------------------------
             Poster #839                                                    
  Mifepristone Reduced U500 Insulin                                         
   Usage in a Patient with Cushing       Kimberley A. Bourne, M.D., FACE    
  Disease and Normalized Concomitant           James J. Smith, PhD          
 Fatty Liver Disease and Retinopathy                                        
----------------------------------------------------------------------------

About Corcept Therapeutics Incorporated
Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol. Korlym®, a first-generation cortisol modulator, is the company's first FDA-approved medication. The company has a portfolio of proprietary compounds that modulate the effects of cortisol but not progesterone. Corcept owns extensive intellectual property covering the use of cortisol modulators, including mifepristone, in the treatment of a wide variety of serious disorders, including Cushing's syndrome. It also holds composition of matter patents covering its selective cortisol modulators.


CONTACT:
Charles Robb
Chief Financial Officer
Corcept Therapeutics
650-688-8783
Email Contact
www.corcept.com

Back to news